CD8A and hepatocellular carcinoma: Synergy with anti-PD-1 blockade substantially reprogrammed the immune microenvironment, leading to tumor regression, compared to current therapeutic strategies for HCC.<h4>Conclusions</h4>FAK inhibitors can enhance the sensitivity of HCC to anti-PD-1 therapy by inhibiting angiogenesis and fibrosis and promoting CD8<sup>+</sup> T cell infiltration.